The Christchurch Clinical Studies Trust is pleased to report that to date 115 volunteers have been dosed in the MANE Clinical Study.

This study is sponsored by Merck KGaA (Darmstadt, Germany).

The coordinating investigator is Dr Chris Wynne, the Medical Director of CCST.

This is a randomised, double blind, parallel group, controlled study to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adults.

The study recruitment is expected to run until November 2107.